NorthStar Medical Radioisotopes

NorthStar Medical Radioisotopes is a commercial-stage nuclear medicine company focused on advancing patient care by providing diagnostic and therapeutic radioisotopes, novel radiopharmaceuticals, and customized radiopharmaceutical development services. Its proven management team and state-of-the-art, environmentally preferable, and non-uranium based technologies have made it an emerging leader at the forefront of US medical radioisotope and radiopharmaceutical production.

NorthStar is the sole domestic producer of molybdenum-99 (Mo-99), used to generate the standard-of-care diagnostic imaging radioisotope technetium-99 million (Tc-99 million) for assessing heart disease and cancer. In March 2022, the company announced it had generated over one million doses of Tc-99 million for patients' diagnostic imaging studies using its innovative RadioGenix System. NorthStar's unique Mo-99 production process using electron accelerator technology results in benign, short-lived waste compared to traditional uranium-based methods.

The company is expanding its industry-leading position in the therapeutic radioisotope area, used in targeted radiopharmaceutical therapy to treat cancer and other serious diseases. Using its environmentally preferable electron accelerator technology, NorthStar is poised to be the first commercial-scale producer of the therapeutic radioisotopes copper-67 (Cu-67) and non-carrier-added actinium-225 (n.c.a. Ac-225). In March 2023, the company announced the delivery and installation of a custom-built accelerator at its new Ac-225 Production facility in Beloit, Wisconsin, with initial radiochemical grade Ac-225 production planned for late 2023.

NorthStar's Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO/CMO) services unit will provide customized service offerings and specialized radiopharmaceutical expertise to help biopharmaceutical companies rapidly advance their development and commercialization programs.